{"id":32225,"date":"2017-04-12T12:00:00","date_gmt":"2017-04-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/"},"modified":"2017-04-12T12:00:00","modified_gmt":"2017-04-12T12:00:00","slug":"novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/","title":{"rendered":"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1391 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates 2016<\/h2>\n<p>La profesora Claire Hopkins (Reino Unido) modera esta sesi\u00f3n para debatir sobre los nuevos anticuerpos monoclonales para la rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN). Los puntos tratados en este debate se centran en las necesidades no cubiertas, el desaf\u00edo de los nuevos tratamientos, las cuestiones a considerar por el panel y el dupilumab en la inflamaci\u00f3n de tipo 2. <\/p>\n<h3>Panelistas<\/h3>\n<p>Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens y Prof. Peter Hellings.<\/p>\n<\/div><\/div>\n<\/p><\/div>\n<p>,  <\/p>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1392 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\">\n<center><iframe width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/D9PBHqQU9GM?rel=0\" title=\"Reproductor de v\u00eddeo de YouTube\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/center>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates 2016 La profesora Claire Hopkins (Reino Unido) modera esta sesi\u00f3n para debatir sobre los nuevos anticuerpos monoclonales para la rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN). Los puntos tratados en este debate se centran en las necesidades no cubiertas, el desaf\u00edo de los nuevos tratamientos, las cuestiones a considerar por el panel y el dupilumab en la inflamaci\u00f3n de tipo 2. Panelistas Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens y Prof. Peter Hellings. ,<\/p>\n","protected":false},"author":1,"featured_media":32243,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[202],"tags":[179,203,205,206,209],"class_list":["post-32225","news","type-news","status-publish","has-post-thumbnail","hentry","category-debates-futuros-de-rinologia","tag-biologicos","tag-rinologia","tag-debates","tag-debates-futuros-de-rinologia","tag-rinosinusitis-cronica-rsc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates 2016 La profesora Claire Hopkins (Reino Unido) modera esta sesi\u00f3n para debatir sobre los nuevos anticuerpos monoclonales para la rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN). Los puntos tratados en este debate se centran en las necesidades no cubiertas, el desaf\u00edo de los nuevos tratamientos, las cuestiones a considerar por el panel y el dupilumab en la inflamaci\u00f3n de tipo 2. Panelistas Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens y Prof. Peter Hellings. ,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/\",\"name\":\"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"datePublished\":\"2017-04-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/elige-tu-camino\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/","og_locale":"es_ES","og_type":"article","og_title":"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN","og_description":"Rhinology Future Debates 2016 La profesora Claire Hopkins (Reino Unido) modera esta sesi\u00f3n para debatir sobre los nuevos anticuerpos monoclonales para la rinosinusitis cr\u00f3nica con p\u00f3lipos nasales (RSCcPN). Los puntos tratados en este debate se centran en las necesidades no cubiertas, el desaf\u00edo de los nuevos tratamientos, las cuestiones a considerar por el panel y el dupilumab en la inflamaci\u00f3n de tipo 2. Panelistas Prof. Claus Bachert, Prof. Manuel Bernal, Prof. Wytske Fokkens y Prof. Peter Hellings. ,","og_url":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/","url":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/","name":"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","datePublished":"2017-04-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/es\/news\/novedades-en-el-desarrollo-de-biologicos-para-la-rsccpn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.euforea.org\/es\/elige-tu-camino\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/es\/news\/"},{"@type":"ListItem","position":3,"name":"Novedades en el desarrollo de biol\u00f3gicos para la RSCcPN"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/es\/#website","url":"https:\/\/www.euforea.org\/es\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/es\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.euforea.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/32225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/comments?post=32225"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/news\/32225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media\/32243"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/media?parent=32225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/categories?post=32225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/es\/wp-json\/wp\/v2\/tags?post=32225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}